FAQs on IPF Therapies: Current, Emerging, and Combination Strategies

Why It Matters

These developments broaden therapeutic choices for a disease with high mortality, potentially extending survival and improving quality of life while influencing payer reimbursement strategies.

Key Takeaways

• Three FDA‑approved IPF drugs slow forced vital capacity decline.
• Nerandomilast approved 2025, first new IPF therapy in decade.
• Nintedanib shows better cost‑effectiveness than pirfenidone in US.
• Inhaled treprostinil shows promise in phase‑3 IPF trials.
• Combination therapy under study to improve outcomes without added risk.

Pulse Analysis

Idiopathic pulmonary fibrosis remains a leading cause of progressive lung failure, affecting thousands of patients worldwide. The current therapeutic landscape is anchored by three FDA‑approved antifibrotics—nerandomilast, nintedanib, and pirfenidone—each targeting distinct pathways such as phosphodiesterase‑4B inhibition, tyrosine‑kinase signaling, and anti‑inflammatory mechanisms. Clinical data consistently demonstrate modest slowing of forced vital capacity decline, translating into measurable survival benefits for a subset of patients, while also highlighting the disease’s unmet need for more potent, tolerable options.

Economic considerations are increasingly shaping treatment decisions. A systematic review of nine cost‑effectiveness studies concluded that nintedanib generally offers a more favorable incremental cost‑effectiveness ratio compared with pirfenidone, though absolute values vary widely across health systems. Meanwhile, real‑world surveys reveal that up to 90% of patients experience at least one adverse event, underscoring the trade‑off between efficacy and quality‑of‑life impacts. Payers are therefore scrutinizing both clinical outcomes and budgetary implications, prompting interest in value‑based pricing models and outcome‑linked reimbursement.

The pipeline promises to reshape IPF management in the coming years. Inhaled treprostinil, already approved for pulmonary hypertension, has shown encouraging phase‑3 results for IPF, offering a targeted delivery route that may reduce systemic toxicity. Deupirfenidone, a deuterated pirfenidone analogue, has earned orphan‑drug designation, suggesting potential pharmacokinetic advantages. Moreover, investigators are testing combination regimens that pair existing antifibrotics with novel agents, aiming to synergistically curb fibrotic signaling without replicating immunosuppressive harms seen in earlier trials. If these strategies prove safe and effective, they could extend survival, lower hospitalization rates, and shift the standard of care toward a more personalized, multi‑modal approach.